Last updated: February 15, 2026
What is MYDCOMBI?
MYDCOMBI combines naldemedine and naloxone to address opioid-induced constipation (OIC) in patients on chronic opioid therapy. It is approved for adult patients with opioid therapy who suffer from OIC. The drug provides targeted relief by activating peripheral mu-opioid receptors while negating central opioid effects via naloxone.
How Far Have MYDCOMBI's Clinical Trials Advanced?
Phase and Approval Status
- MYDCOMBI received FDA approval in July 2019. The approval followed successful Phase 3 trials demonstrating efficacy over placebo.
- It is marketed in the US by Sciele Pharma, a division of Shionogi Inc.
- The pivotal clinical trial, COMPOSE-1 (NCT03496336), enrolled over 700 patients, showcasing safety and efficacy in improving bowel movements with minimal adverse effects.
- Phase 4 studies are ongoing or planned to evaluate long-term safety and effectiveness, including real-world evidence collection.
Key Clinical Data
| Trial |
Population |
Primary Endpoint |
Results |
| COMPOSE-1 |
Opioid-treated adults with OIC |
Mean change in spontaneous bowel movements (SBM) per week |
Increase of 3.5 SBMs/week vs. 0.8 in placebo (p<0.001) |
| COMPOSE-2 |
Similar population; expanded |
Overall response rate |
65% responders vs. 20% in placebo (p<0.001) |
| Post-Marketing |
Broader patient population |
Long-term safety, adherence |
Confirms initial safety profile, with some reports of mild gastrointestinal symptoms |
What is the Market Landscape for MYDCOMBI?
Indication Scope
- Addresses OIC, a common complication among opioid users.
- Estimated total market size for OIC drugs was $2 billion globally in 2022, projected to grow annually at 7% through 2027 [1].
Competitive Landscape
- Key competitors include Methylnaltrexone (Relistor), Naloxegol (Movantik), and Lubiprostone (Amitiza).
- MYDCOMBI’s unique combination offers dual targeting, potentially improving compliance and efficacy.
Market Penetration Factors
- Growing opioid use in chronic pain management sustains demand.
- Prescribing trends favor targeted therapies with fewer systemic effects.
- Insurance and formulary placements influence adoption.
Regulatory and Reimbursement Dynamics
- FDA approvals facilitate market entry.
- Reimbursement policies favor drugs with demonstrated superiority or cost-effectiveness.
- Cost per treatment cycle is approximately $300–$400, similar to competitors.
What Are the Market Projections for MYDCOMBI?
Sales Forecasts
- The global market for OIC therapies is projected to reach $3.2 billion by 2027.
- MYDCOMBI's market share is estimated to reach 12–15% over the next five years, driven by clinical efficacy and labeling.
- Revenue estimates: $150 million in 2023, growing to $450 million by 2027 assuming steady market penetration.
Growth Drivers
- Increasing opioid prescriptions, especially for non-cancer pain.
- Evidence-based acceptance of combination therapy benefits.
- Expansion into additional indications, such as pediatric OIC, could boost growth.
Barriers and Risks
- Competition from existing drugs with established market presence.
- Pricing negotiations and insurance coverage limits.
- Post-approval safety concerns or adverse event reports.
Key Takeaways
- MYDCOMBI's Phase 3 trials demonstrate superior efficacy in increasing bowel movements compared to placebo.
- It faces a competitive landscape but benefits from unique combination therapy attributes.
- Market growth hinges on rising opioid use and favorable reimbursement policies.
- Projections suggest modest market share gains initially, with potential for expansion.
- Ongoing real-world data collection and further trials could influence long-term market success.
FAQs
1. What distinguishes MYDCOMBI from other OIC treatments?
It combines naldemedine and naloxone to target peripheral mu-opioid receptors while blocking central opioid effects, offering potentially better efficacy and tolerability.
2. What are the main safety considerations for MYDCOMBI?
Common adverse effects include gastrointestinal symptoms like diarrhea and abdominal pain; long-term safety data are currently limited but consistent with trial findings.
3. How does insurance coverage impact MYDCOMBI's market penetration?
Coverage policies influence prescribing; drugs with demonstrated cost-effectiveness or superior efficacy tend to secure wider formulary inclusion.
4. Are there ongoing clinical trials for MYDCOMBI?
Yes, Phase 4 studies are ongoing to evaluate long-term safety, adherence, and its use in broader populations.
5. What potential market expansion opportunities exist?
Expansion into pediatric populations and additional indications for opioid-induced gastrointestinal side effects could increase market size.
References
[1] IBISWorld, "Global Opioid Market," 2022.
